HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy.

Abstract
An inherited deficiency of β-galactosylceramidase (GALC) causes the lysosomal storage disease globoid cell leukodystrophy (GLD). The disease is characterized by the accumulation of the cytotoxic metabolite psychosine (galactosylsphingosine), causing rapid degeneration of myelinating cells. Most patients suffer from the infantile form of GLD with onset of disease between 3 and 6 months after birth and death by 2 years of age. The most widely used animal model of GLD, the twitcher mouse, presents with an even more rapid course of disease and death around 40 days of age. We have generated a novel "humanized" mouse model of GLD by inserting a human GALC cDNA containing an adult-onset patient mutation into the murine GALC gene. Humanized GALC mice exhibit pathological hallmarks of GLD including psychosine accumulation, neuroinflammation, CNS infiltration of macrophages, astrogliosis and demyelination. Residual GALC activities in mouse tissues are low and the mice display a median lifespan of 46 days. Due to the expression of the human transgene, the mice do not develop an immune response against rhGALC, rendering the animal model suitable for therapies based on human enzyme. Intravenously injected rhGALC was able to surmount the blood-brain barrier and was targeted to lysosomes of brain macrophages, astrocytes and neurons. High-dose enzyme replacement therapy started at postnatal day 21 reduced the elevated psychosine levels in the peripheral and central nervous system by 14-16%, but did not ameliorate neuroinflammation, demyelination and lifespan. These results may indicate that treatment must be started earlier before pathology occurs.
AuthorsFrank Matthes, Claes Andersson, Axel Stein, Carl Eistrup, Jens Fogh, Volkmar Gieselmann, David A Wenger, Ulrich Matzner
JournalExperimental neurology (Exp Neurol) Vol. 271 Pg. 36-45 (Sep 2015) ISSN: 1090-2430 [Electronic] United States
PMID25956830 (Publication Type: Journal Article)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Cytokines
  • Nerve Tissue Proteins
  • Psychosine
  • Galactosylceramidase
Topics
  • Age Factors
  • Animals
  • Animals, Newborn
  • Body Weight (genetics)
  • Central Nervous System (enzymology)
  • Cytokines (metabolism)
  • Disease Models, Animal
  • Enzyme Replacement Therapy (methods)
  • Female
  • Galactosylceramidase (genetics, metabolism)
  • Gene Expression Regulation (drug effects, genetics)
  • Humans
  • Leukodystrophy, Globoid Cell (enzymology, genetics, pathology, therapy)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Transgenic
  • Mutation (genetics)
  • Myelin Sheath (metabolism)
  • Nerve Tissue Proteins (metabolism)
  • Psychosine (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: